Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Protalix BioTherapeutics (PLX) EPS (Weighted Average and Diluted) (2016 - 2025)

Protalix BioTherapeutics has reported EPS (Weighted Average and Diluted) over the past 13 years, most recently at -$0.07 for Q4 2025.

  • Quarterly results put EPS (Weighted Average and Diluted) at -$0.07 for Q4 2025, down 177.78% from a year ago — trailing twelve months through Dec 2025 was -$0.09 (down 400.0% YoY), and the annual figure for FY2025 was -$0.08, down 300.0%.
  • EPS (Weighted Average and Diluted) for Q4 2025 was -$0.07 at Protalix BioTherapeutics, down from $0.03 in the prior quarter.
  • Over the last five years, EPS (Weighted Average and Diluted) for PLX hit a ceiling of $0.21 in Q2 2023 and a floor of -$0.25 in Q2 2021.
  • Median EPS (Weighted Average and Diluted) over the past 5 years was -$0.06 (2024), compared with a mean of -$0.05.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): crashed 566.67% in 2021 and later skyrocketed 290.91% in 2023.
  • Protalix BioTherapeutics' EPS (Weighted Average and Diluted) stood at -$0.14 in 2021, then soared by 50.0% to -$0.07 in 2022, then changed by 0.0% to -$0.07 in 2023, then skyrocketed by 228.57% to $0.09 in 2024, then tumbled by 177.78% to -$0.07 in 2025.
  • The last three reported values for EPS (Weighted Average and Diluted) were -$0.07 (Q4 2025), $0.03 (Q3 2025), and -$0.05 (Q1 2025) per Business Quant data.